1. Home
  2. GH vs AROC Comparison

GH vs AROC Comparison

Compare GH & AROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • AROC
  • Stock Information
  • Founded
  • GH 2011
  • AROC 1990
  • Country
  • GH United States
  • AROC United States
  • Employees
  • GH N/A
  • AROC N/A
  • Industry
  • GH Medical Specialities
  • AROC Oil & Gas Production
  • Sector
  • GH Health Care
  • AROC Energy
  • Exchange
  • GH Nasdaq
  • AROC Nasdaq
  • Market Cap
  • GH 4.9B
  • AROC 4.2B
  • IPO Year
  • GH 2018
  • AROC 1997
  • Fundamental
  • Price
  • GH $65.46
  • AROC $24.22
  • Analyst Decision
  • GH Strong Buy
  • AROC Buy
  • Analyst Count
  • GH 22
  • AROC 6
  • Target Price
  • GH $64.91
  • AROC $30.00
  • AVG Volume (30 Days)
  • GH 2.2M
  • AROC 1.6M
  • Earning Date
  • GH 10-29-2025
  • AROC 10-28-2025
  • Dividend Yield
  • GH N/A
  • AROC 3.46%
  • EPS Growth
  • GH N/A
  • AROC 49.93
  • EPS
  • GH N/A
  • AROC 1.33
  • Revenue
  • GH $828,849,000.00
  • AROC $1,348,892,000.00
  • Revenue This Year
  • GH $28.30
  • AROC $31.13
  • Revenue Next Year
  • GH $22.98
  • AROC $6.46
  • P/E Ratio
  • GH N/A
  • AROC $18.26
  • Revenue Growth
  • GH 28.74
  • AROC 28.23
  • 52 Week Low
  • GH $20.14
  • AROC $19.73
  • 52 Week High
  • GH $68.23
  • AROC $30.44
  • Technical
  • Relative Strength Index (RSI)
  • GH 59.00
  • AROC 46.00
  • Support Level
  • GH $61.00
  • AROC $23.67
  • Resistance Level
  • GH $68.22
  • AROC $24.81
  • Average True Range (ATR)
  • GH 2.50
  • AROC 0.85
  • MACD
  • GH 0.12
  • AROC -0.17
  • Stochastic Oscillator
  • GH 64.47
  • AROC 22.82

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About AROC Archrock Inc.

Archrock Inc is an energy infrastructure company with a focus on midstream natural gas compression and a commitment to helping customers produce, compress, and transport natural gas. It has two business segments, Contract Operations, and Aftermarket Services. Under the umbrella of contract operations services, the company provides operations to meet customers' natural gas compression needs. Services include designing, owning, installing, operating, and maintaining equipment. Aftermarket Services business provides a full range of services to support the compression needs of customers who own compression equipment, including operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components. It generates maximum revenue from the Contract Operations segment.

Share on Social Networks: